Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ALK-abello A/S Class B (AKBLF)
OTHER OTC:AKBLF
Holding AKBLF?
Track your performance easily
Earnings Data
Report Date
Feb 19, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.17Last Year’s EPS
0.09Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 09, 2018
|% Change Since: -9.18%
|Next Earnings Date:Aug 15, 2018
Earnings Call Sentiment|Positive
The earnings call presented a robust performance in several areas, including strong organic revenue growth and significant improvements in EBIT margin. Recovery in Jext sales and a major licensing deal with ARS Pharma highlight strategic advancements. However, challenges remain in North America with sluggish growth, underperformance of PRE-PEN, and delays in the Chinese market. Overall, the positives slightly outweigh the negatives, indicating a generally optimistic outlook.Company Guidance
During the Q3 2024 earnings call for ALK B.CO, significant guidance was provided reflecting strong performance and strategic advancements. The company reported an 18% organic revenue growth, with tablets showing an impressive 29% global growth, specifically 27% in Europe. Jext sales rebounded, contributing to a 10 percentage point increase in the EBIT margin, from 13% to 23%. The Allergy+ strategy is progressing well, highlighted by a licensing agreement with ARS Pharma for the neffy nasal spray. In China, progress is being made to resume the regulatory approval process for the house dust mite product. Looking forward, ALK B.CO maintains its full-year outlook, anticipating 14% to 16% top line growth, with an EBIT margin between 19% and 21%. The implementation of the Allergy+ strategy and the new in-licensing deal are set to contribute to future growth and align with ALK's long-term financial ambitions.Strong Organic Revenue Growth
ALK reported an 18% organic revenue growth across regions and product lines with a notable 29% global growth in tablets, particularly 27% in Europe.
EBIT Margin Improvement
The EBIT margin increased by 10 percentage points year-on-year, from 13% to 23%, driven by sales growth, gross margin improvements, resource optimization, and cost savings.
Recovery in Jext Sales
Sales of the adrenaline auto-injector Jext rebounded and fully recovered from last year's supply shortages, contributing to a 26% increase in global revenue from other products and services.
Licensing Deal with ARS Pharma
ALK entered a significant in-licensing deal with ARS Pharma for the neffy nasal spray, marking the largest in-licensing deal in ALK's history, with an upfront payment of USD 145 million.
Positive Free Cash Flow
Free cash flow improved to DKK 425 million as higher earnings offset changes in working capital and investments.
---
AKBLF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AKBLF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $22.88 | $22.60 | -1.22% |
| Aug 22, 2024 | $23.95 | $24.12 | +0.71% |
| May 02, 2024 | $18.68 | $18.58 | -0.54% |
| Feb 08, 2024 | $16.40 | $17.31 | +5.55% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does ALK-abello A/S Class B (AKBLF) report earnings?
ALK-abello A/S Class B (AKBLF) is schdueled to report earning on Feb 19, 2025, TBA Not Confirmed.
What is ALK-abello A/S Class B (AKBLF) earnings time?
ALK-abello A/S Class B (AKBLF) earnings time is at Feb 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AKBLF EPS forecast?
AKBLF EPS forecast for the fiscal quarter 2024 (Q4) is 0.17.
---